147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Applications
Therapy areas
More posts

Méthode d’imagerie ultrasonore 4d très large champ de vue par

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, […]

Antagonists of il-33 for use in methods for preventing ischemia

Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, […]

Methods and pharmaceutical compositions for the treatment of

The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. In particular, the […]

A b cell depleting agent for the treatment of atherosclerosis or post

New anti-atherogenic strategies based on B cell modulation, and suggest that patients currently treated with CD20 antibodies for other immune-mediated […]

Monoacylglycerol lipase as target for the treatment of liver fibrosis

The present invention relates to methods and pharmaceutical compositions for the treatment of fibrosis. In particular, the present invention relates […]

Treatment of bone mineral density related diseases

The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present […]

Use of cd9 as a biomarker and as a biotarget in glomerulonephritis

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) […]

Ngal as a novel target for the treatment of chronic kidney disease

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, […]

Ppar-gamma agonist as target for the treatment of rapidly progressive

This study demonstrates the pivotal role of the local PPAR-gamma agonist system in maintaining podocyte quiescence and orchestrating the global […]

Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling

Markers of an intense scarring process in the early phase post- myocardial infarction (MI) are still undetermined, and the identification of patients […]

More posts

You might also be interested in